Quick Facts

• Main Therapeutic Domain: Management of symptomatic hypoglycemia (low blood sugar).
• Key Indication: Hypoglycemia caused by hyperinsulinism (excessive insulin release).
• Conditions Addressed: Hyperinsulinism associated with specific conditions, including inoperable islet cell tumors or extrapancreatic malignancy in adults.
• Pediatric Use: Used in infants and children for hyperinsulinism linked to conditions such as islet cell hyperplasia or nesidioblastosis.

---

Proglycem is an approved medication utilized for the management of symptomatic hypoglycemia, or abnormally low blood glucose levels. Its primary therapeutic benefit is in helping to elevate blood sugar levels in individuals who experience hyperinsulinism, which is the excessive release of insulin from the pancreas.

For adult patients, the treatment is indicated for hypoglycemia associated with certain serious conditions, such as inoperable tumors of the pancreatic islet cells (adenoma or carcinoma) or tumors originating outside the pancreas (extrapancreatic malignancy).

In infants and children, Proglycem may be beneficial in managing hypoglycemia related to hyperinsulinism caused by several specific conditions. These conditions may include leucine sensitivity, nesidioblastosis, islet cell hyperplasia, or similar tumors of the islet cells. The medication may be used as a temporary measure before or after surgery if low blood sugar persists. Treatment should be considered when other specific medical therapies or surgical options have been unsuccessful or are not feasible. The therapeutic goal is to stabilize blood glucose levels.

Proglycem (diazoxide) is only officially approved for use in patients whose low blood sugar (hypoglycemia) is caused by hyperinsulinism (the body making too much insulin) associated with specific, documented conditions.

---

Populations for Whom Use is Prohibited

The medicine is contraindicated (must not be used) in two primary groups according to regulatory labeling:

• Patients with functional hypoglycemia (low blood sugar that is not caused by hyperinsulinism).
• Patients with known hypersensitivity or allergy to diazoxide or to other thiazides (due to potential cross-sensitivity).

---

Age-Related Eligibility and Restrictions

Age Group	Official Regulatory Status
Infants and Children	Use is established for hypoglycemia due to hyperinsulinism. Newborns and infants require close monitoring for conditions like pulmonary hypertension.
Adults	Use is established for hyperinsulinism-related hypoglycemia (e.g., associated with inoperable tumors).
Older Adults	No specific data are available on the relationship of age to the effects in the geriatric population.

---

Special Population Limitations

• Pregnancy: Safety has not been established in pregnant women. Use is considered only if the potential benefits outweigh the possible risks to the fetus.
• Breastfeeding: A decision must be made to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother, as the potential for adverse reactions in the infant is a concern.
• Renal or Cardiac Impairment: Patients with impaired renal function or compromised cardiac reserve require special caution and close monitoring for fluid retention, which may require adjustment.

Interaction Map: Interactions with other medicines and products — official regulatory information for Proglycem

Interaction Scope

Category	Official Regulatory Statements
Medicinal product categories with documented interactions	Thiazide and other Benzothiazide Diuretics, Antihypertensive Agents, Coumarin and its derivatives (Anticoagulants).
Specific interacting medicines (if explicitly listed)	Diphenylhydantoin (Phenytoin).
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: Displacement (Displacement of highly protein-bound substances). Pharmacodynamic: Potentiation (Enhancement or additive effects on blood glucose and blood pressure).
Timing-based interaction rules (if applicable)	None explicitly described in the primary regulatory labeling documents reviewed.
Population-specific interaction notes (if applicable)	The plasma half-life of diazoxide is prolonged in patients with impaired renal function.
Interaction-related restrictions	Contraindicated in patients with Functional Hypoglycemia.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Statements
Interaction severity classification (as defined in official documents)	Contraindicated (for Functional Hypoglycemia). Clinically significant (due to potentiation and displacement).
Regulatory basis (EMA / FDA / etc.)	U.S. Food and Drug Administration (FDA) Prescribing Information; National Drug Monograph.
Interaction-context constraints (as defined in official documents)	Interactions with herbal products are not established.

---

Resulting Interaction Structure

Official Interaction Statements:

• Co-administration with thiazide and other benzothiazide diuretics may potentiate the hyperglycemic and hyperuricemic effects of diazoxide.
• The antihypertensive effect of other concurrently administered antihypertensive agents may be enhanced.
• Due to high protein-binding, diazoxide may displace Coumarin and its derivatives (anticoagulants), leading to higher blood levels of the anticoagulant.
• Displacement of bilirubin from albumin may also occur, resulting in higher blood levels of bilirubin.
• Concomitant administration with Diphenylhydantoin (Phenytoin) may result in a loss of seizure control.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product’s interaction structure primarily around pharmacodynamic potentiation with medicines affecting blood sugar and blood pressure, and pharmacokinetic displacement involving highly protein-bound medicines. This profile is further shaped by an explicit regulatory contraindication related to a specific disease state (Functional Hypoglycemia) and a population-specific pharmacokinetic constraint related to renal impairment.

Proglycem, whose active pharmaceutical ingredient is diazoxide, functions as an ATP-sensitive potassium channel (KATP) agonist. Its primary pharmacodynamic target is the Kir6.2/SUR1 complex that constitutes the KATP channel located on the plasma membrane of pancreatic beta cells .

Diazoxide binds to the sulfonylurea receptor 1 (SUR1) subunit, inducing a conformational change that promotes the opening of the KATP channel. This interaction results in an efflux of potassium ions (K^+) from the beta cell, leading to hyperpolarization of the cellular membrane.

The hyperpolarized state subsequently inhibits the activation and opening of voltage-dependent L-type calcium channels (Ca^2+), thereby reducing the intracellular calcium concentration. The resulting lower intracellular calcium levels ultimately inhibit the fusion of insulin secretory vesicles with the cell membrane, modulating the exocytotic release of insulin. The system-level physiological consequence is a direct increase in the circulating concentration of glucose.

How Proglycem is Used

Proglycem (diazoxide) is an oral medication prescribed for the long-term management of symptomatic hypoglycemia. Its administration is standardized to ensure precise and consistent intake, with dosage primarily determined by the patient's body weight and age.

---

Administration Guidelines

Administration Scope	Detail
Route of Administration	Oral administration only.
Dosing Schedule	Highly individualized and weight-based ( mg/kg/day), titrated according to clinical and laboratory response.
Frequency and Timing	The total daily dose is divided into two or three equal portions, generally administered every 8 to 12 hours.
Timing in Relation to Meals	May be taken with or without food.

---

Population and Procedural Rules

Guidelines establish different dosing ranges for specific age groups. The maximum daily dose for adults and older children is typically 8 mg/kg/day. Newborns and infants may start at a higher dose and can be titrated up to 15 mg/kg/day.

For the oral suspension form (50 mg/mL), accurate measurement using a calibrated device is necessary. Furthermore, patients with renal impairment may require a reduced dosage due to the drug's prolonged presence in the bloodstream. Treatment should be discontinued if effectiveness is not observed after a two- to three-week trial period. If a scheduled dose is missed, it should be skipped if it is almost time for the next administration, and doses should never be doubled.

Proglycem: Recent Clinical Evidence

1. Evidence for use in Hyperinsulinemic Hypoglycemia in Infants and Children

This section summarizes the structure of the evidence available for Proglycem in children, primarily drawing from systematic reviews and meta-analyses of multiple observational cohort studies. Research was studied in the context of persistent low blood sugar (hyperinsulinism) in infants and children, and studies monitored blood glucose patterns and clinical response status across different patient groups. Findings from this aggregated research show patterns related to blood glucose levels in the studied populations, and also contributes to understanding long-term developmental outcomes. However, certainty remains low because the data are not supported by multiple large-scale randomized controlled trials (RCTs). Instead, research relies on observational studies where evidence quality varies and statistical heterogeneity (inconsistency) is noted across combined findings.

2. Evidence for use in Tumor-Related Hyperinsulinism in Adults

Research exploring the use of Proglycem for adults experiencing hypoglycemia due to certain inoperable pancreatic or extrapancreatic tumors is limited. The research base consists mainly of regulatory evidence summaries, small case series, and individual case reports that document clinical experience. These studies research describes the observed patterns related to blood glucose levels and the duration of glucose control that was observed. The evidence base is restricted to these types of reports; there is a lack of comparative evidence and no prospective, controlled trials focused on these rare adult conditions. Consequently, certainty remains low for this specific clinical context.

3. Long-term Studies and Follow-up Data

Researchers have explored the long-term effects of Proglycem, particularly in pediatric patients who may receive the medication for many years. Long-term observational studies track follow-up periods extending to multiple years, focusing on neurodevelopmental and cognitive outcomes over time. However, limited information for long-term outcomes is available when measured through standardized clinical trials. While research provides context for the blood glucose patterns observed in many patients, the long-term effects are not fully established or characterized by multiple comparative studies spanning decades.

4. Evidence in Special Subpopulations and Research Gaps

Studies have research examined different special populations based on underlying cause, exploring differences in clinical response between patients with distinct genetic defects (e.g., K-ATP channel status). Findings indicate that the rate of response may vary significantly, and data show patterns related to certain genetic subtypes being consistently unresponsive to the medication. This means results apply only to the populations studied. Overall, the evidence base includes several gaps: comparative evidence is lacking against other therapies, data for certain groups remain insufficient (such as adults), and follow-up durations were limited in many studies.

Key Studies & References

1. Management of congenital hyperinsulinism: a systematic review and consensus guideline

Storage & Disposal Map: How to Store and Dispose of Proglycem — Official Regulatory Information

Labeled storage temperature requirements: Controlled Room Temperature of 25 C (77 F), with permissible temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be kept from freezing.

Light/moisture protection requirements: Protect from light and store in a light-resistant container. The suspension must be kept in the original carton until use to maintain this protection.

Stability and Handling requirements: Requires shaking well before using. The suspension should be discarded if it has turned a dark color, as this may indicate reduced potency.

Child-protection storage requirements: This medicine must be kept out of the reach of children.

Disposal instructions (as documented in government sources): Unused or expired medicine should not be kept. Patients are instructed to consult a healthcare professional or pharmacist for specific guidance on how to properly discard any medication that is no longer needed.